Replimune (REPL) EBT (2017 - 2026)

Replimune has reported EBT for 10 years, with the latest figure at -$73.5 million in Q1 2026.

• Quarterly EBT rose 1.05% year-over-year to -$73.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$396.3 million (down 60.57% YoY) and the FY2026 annual result came in at -$314.5 million, down 27.41% from the prior year.
• EBT retreated to -$73.5 million in Q1 2026 per REPL's latest filing, from -$71.2 million in the prior quarter.
• Over five years, EBT peaked at -$31.6 million in Q1 2022 and troughed at -$128.7 million in Q2 2025.
• A 5-year average of -$62.6 million and a median of -$53.8 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2025: EBT surged 51.52% in 2022, then plunged 139.39% in 2025.
• Over 5 years, EBT stood at -$39.7 million in 2022, then decreased by 27.61% to -$50.6 million in 2023, then retreated by 29.85% to -$65.8 million in 2024, then retreated by 8.33% to -$71.2 million in 2025, then decreased by 3.11% to -$73.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$73.5 million, -$71.2 million, and -$122.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.